|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquired
|
gptkb:Organon
|
|
gptkbp:acquired_by
|
gptkb:Merck_&_Co.
|
|
gptkbp:acquisition
|
gptkb:Partnerships
$41 billion
Schering-Plough acquired Organon in 2007
|
|
gptkbp:acquisition_year
|
gptkb:2007
|
|
gptkbp:dissolved
|
gptkb:2014
|
|
gptkbp:employees
|
25,000
approximately 26,000 (2008)
|
|
gptkbp:established
|
gptkb:2000
|
|
gptkbp:founded
|
gptkb:Schering_Corporation
1851
|
|
gptkbp:headquarters
|
gptkb:Kenilworth
gptkb:USA
gptkb:Kenilworth,_New_Jersey,_USA
gptkb:Kenilworth,_New_Jersey
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Schering-Plough
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:key_people
|
gptkb:Fred_Hassan
R. A. H. van der Velden
|
|
gptkbp:market
|
global
|
|
gptkbp:merged_with
|
gptkb:Merck_&_Co.
merger with Schering AG in 2000
|
|
gptkbp:notable_person
|
gptkb:Fred_Hassan
|
|
gptkbp:notable_products
|
gptkb:Claritin
gptkb:Nuva_Ring
gptkb:Remicade
gptkb:Aldactone
gptkb:Kogenate
|
|
gptkbp:parent_company
|
gptkb:Merck_&_Co.
|
|
gptkbp:products
|
drugs
cancer treatments
allergy medications
|
|
gptkbp:research_and_development
|
focus on oncology, immunology, and cardiovascular diseases
|
|
gptkbp:revenue
|
$18.5 billion (2008)
$18.5 billion
|
|
gptkbp:stock_symbol
|
SGP
|
|
gptkbp:subsidiaries
|
gptkb:Schering_Corporation
|
|
gptkbp:subsidiary
|
gptkb:Merck_&_Co.
|
|
gptkbp:type
|
gptkb:pharmaceuticals
|
|
gptkbp:website
|
www.schering-plough.com
|
|
gptkbp:bfsParent
|
gptkb:Merck_&_Co.
|
|
gptkbp:bfsLayer
|
4
|